Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension
Sayeh Heidari Nejad, Omar Azzam, Markus P. Schlaich
Current Hypertension Reports (2023) Vol. 25, Iss. 10, pp. 343-352
Open Access | Times Cited: 10

Showing 10 citing articles:

Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials
Zheng Li, Ming Liu, Xiaotong Gu, et al.
Reviews in Cardiovascular Medicine (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Highlights on U.S. FDA-Approved Halogen-Containing Drugs in 2024
Saghir Ali, Xiaochen Tian, Salvatore A Meccia, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117380-117380
Closed Access | Times Cited: 1
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension
Juan Tamargo
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 5, pp. 371-373
Open Access | Times Cited: 4
Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists
Sayeh Heidari Nejad, Omar Azzam, Markus P. Schlaich
Future Cardiology (2024) Vol. 20, Iss. 9, pp. 435-445
Closed Access | Times Cited: 1
Aprocitentan: a new emerging prospect in the pharmacotherapy of hypertension
Lina Naseralallah, Somaya Koraysh
Blood Pressure (2024) Vol. 33, Iss. 1
Open Access | Times Cited: 1
Entering a New Era of Antihypertensive Therapy
Jordana B. Cohen, Adam P. Bress
American Journal of Kidney Diseases (2023) Vol. 83, Iss. 3, pp. 411-414
Open Access | Times Cited: 3
Medical Measures in Hypertensives Considered Resistant
Fadl Elmula M. Fadl Elmula, Julian E. Mariampillai, Sondre Heimark, et al.
American Journal of Hypertension (2023) Vol. 37, Iss. 5, pp. 307-317
Open Access | Times Cited: 1
Dose Selection for Clinical Development in the Treatment of Hypertension: The Aprocitentan Case and Lessons from the Past
M Bellet, Glenn D. Braunstein, Paul E. Verweij, et al.
Medical Research Archives (2024) Vol. 12, Iss. 1
Open Access
Resistant Hypertension: A Brief Review of Pathophysiology
Alexander Haber, Andrew Foy
Journal of General Internal Medicine (2024)
Closed Access
Vasoactive Substances as Mediators of Renal Injury
Paulo S. Caceres, Noreen F. Rossi
Elsevier eBooks (2024)
Closed Access
Page 1

Scroll to top